Merck
CN
  • The G-250A promoter polymorphism of the hepatic lipase gene predicts the conversion from impaired glucose tolerance to type 2 diabetes mellitus: the Finnish Diabetes Prevention Study.

The G-250A promoter polymorphism of the hepatic lipase gene predicts the conversion from impaired glucose tolerance to type 2 diabetes mellitus: the Finnish Diabetes Prevention Study.

The Journal of clinical endocrinology and metabolism (2004-05-06)
Boryana Todorova, Agata Kubaszek, Jussi Pihlajamäki, Jaana Lindström, Johan Eriksson, Timo T Valle, Helena Hämäläinen, Pirjo Ilanne-Parikka, Sirkka Keinänen-Kiukaanniemi, Jaakko Tuomilehto, Matti Uusitupa, Markku Laakso
摘要

In population-based studies, dyslipidemia related to insulin resistance (high triglyceride level and low high-density lipoprotein cholesterol level) is a risk factor for type 2 diabetes. Therefore, variants in genes regulating lipid and lipoprotein metabolism are potential candidate genes for diabetes. We investigated whether the G-250A polymorphism of the hepatic lipase gene (LIPC) predicts the conversion from impaired glucose tolerance (IGT) to type 2 diabetes in the Finnish Diabetes Prevention Study. This study randomized subjects to either the intervention group (lifestyle modification aimed at weight loss, such as changes in diet and increased physical exercise) or the control group. Genotyping at position -250 of the LIPC gene was performed with PCR amplification, DraI enzyme digestion, and gel electrophoresis in 490 subjects with IGT whose DNA was available. In the entire study population, the conversion rate to type 2 diabetes was 17.8% among subjects with the G-250G genotype and 10.7% among subjects with the -250A allele (P = 0.032). In univariate analysis, the odds ratio for the G-250G genotype to predict the conversion from IGT to type 2 diabetes was 1.80 (95% confidence interval, 1.05-3.10; P = 0.034). In multivariate logistic regression analysis, the G-250G genotype predicted the conversion to diabetes independently of the study group (control or intervention), gender, weight, waist circumference at baseline, and change in weight and waist circumference. In the intervention group, 13.0% of subjects with the G-250G genotype and 1.0% of the subjects with the -250A allele converted to diabetes (P = 0.001). We conclude that the G-250G genotype of the LIPC gene is a risk factor for type 2 diabetes. Therefore, genes regulating lipid and lipoprotein metabolism may be potential candidate genes for type 2 diabetes.

材料
货号
品牌
产品描述

Sigma-Aldrich
脂肪酶 来源于皱褶假丝酵母, Type VII, ≥700 unit/mg solid
Sigma-Aldrich
脂肪酶 来源于猪胰腺, Type II, ≥125 units/mg protein (using olive oil (30 min incubation)), 30-90 units/mg protein (using triacetin)
Sigma-Aldrich
脂肪酶丙烯酸树脂, ≥5,000 U/g, recombinant, expressed in Aspergillus niger
Sigma-Aldrich
重组脂肪酶 B 南极假丝酵母 来源于米曲霉, powder, beige, ~9 U/mg
Sigma-Aldrich
脂肪酶 来源于猪胰腺, Type VI-S, ≥20,000 units/mg protein, lyophilized powder
Sigma-Aldrich
脂肪酶 来源于洋葱假单胞菌, powder, light beige, ≥30 U/mg
Sigma-Aldrich
脂肪酶 来源于黑曲霉, powder (fine), ~200 U/g
Sigma-Aldrich
脂肪酶 来源于皱褶假丝酵母, lyophilized powder, ≥40,000 units/mg protein
Sigma-Aldrich
脂肪酶 来源于念珠菌 属, recombinant, expressed in Aspergillus niger
Sigma-Aldrich
脂肪酶 来源于小麦胚芽, Type I, lyophilized powder, 5-15 units/mg solid
Sigma-Aldrich
固定化脂肪酶 来源于南极假丝酵母, beads, slightly brown, >2 U/mg
Sigma-Aldrich
脂肪酶 来源于米赫根毛霉, ≥20,000 U/g
Sigma-Aldrich
脂肪酶 来源于米根霉, powder (fine), ~10 U/mg
Sigma-Aldrich
脂肪酶 来源于假单胞菌 属, Type XIII, lyophilized powder, ≥15 units/mg solid
Sigma-Aldrich
脂肪酶 来源于米曲霉, lyophilized, powder, white, ~50 U/mg
Sigma-Aldrich
脂肪酶 来源于米黑毛霉菌, powder, slightly brown, ~1 U/mg
Sigma-Aldrich
南极假丝酵母脂肪酶A,重组 来源于米曲霉, powder, beige, ~2 U/mg
Sigma-Aldrich
脂肪酶 来源于皱褶假丝酵母, powder, yellow-brown, ≥2 U/mg
Sigma-Aldrich
脂肪酶 来源于皱褶假丝酵母, lyophilized, powder (fine), 15-25 U/mg
Sigma-Aldrich
脂肪酶 来源于猪胰腺 来源于雪白根霉菌, powder (fine), ≥1.5 U/mg
Sigma-Aldrich
脂肪酶 来源于米黑毛霉菌, lyophilized powder, ≥4,000 units/mg solid (using olive oil)
Sigma-Aldrich
脂肪酶 来源于爪哇毛霉菌, lyophilized powder, ≥300 units/mg solid (using olive oil)